



SUPPLEMENTARY
EUROPEAN SEARCH REPORT

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X, P	YASUNORI YAEGASHI ET AL: "Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis" JOURNAL OF INFECTION AND CHEMOTHERAPY ; OFFICIAL JOURNAL OF THE JAPANESE SOCIETY OF CHEMOTHERAPY AND THE JAPANESE ASSOCIATION FOR INFECTIOUS DISEASES, SPRINGER-VERLAG, TO, vol. 11, no. 5, 1 October 2005 (2005-10-01), pages 234-238, XP019374906 ISSN: 1437-7780 * the whole document * -----	1-18	INV. C07K14/705 C12P21/02 G01N33/53 G01N33/531
X	BUFLER P ET AL: "Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfecteds." EUROPEAN JOURNAL OF IMMUNOLOGY FEB 1995, vol. 25, no. 2, February 1995 (1995-02), pages 604-610, XP002458844 ISSN: 0014-2980	1,2,5	
Y	* abstract; figure 6; table 1 *	3,4, 6-11, 15-18	TECHNICAL FIELDS SEARCHED (IPC)
X	GRUNWALD U ET AL: "An enzyme-linked immunosorbent assay for the quantification of solubilized CD14 in biological fluids." JOURNAL OF IMMUNOLOGICAL METHODS 5 NOV 1992, vol. 155, no. 2, 5 November 1992 (1992-11-05), pages 225-232, XP002458845 ISSN: 0022-1759	12-14	
Y	* abstract; table VI *	3,4, 6-11, 15-18	
		-/-	
2	The supplementary search report has been based on the last set of claims valid and available at the start of the search.		
EPO FORM 1503 03-82 (P04C04)	Place of search	Date of completion of the search	Examiner
	Munich	19 November 2007	RENGGLI-ZULLIGER, N
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			



SUPPLEMENTARY
EUROPEAN SEARCH REPORT

Application Number

EP 05 73 9312

DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Category	Citation of document with indication, where appropriate, of relevant passages		
X	MAJERLE A ET AL: "Bacterial expression and refolding of different fragments of human CD14." PFLÜGERS ARCHIV : EUROPEAN JOURNAL OF PHYSIOLOGY 2000, vol. 439, no. 3 Suppl, 2000, pages R109-R110, XP002458846 ISSN: 0031-6768	1,2,5	
Y	* abstract; figure 1 * -----	3,4	
Y	STELTER FELIX ET AL: "Mutation of amino acids 39-44 of human CD14 abrogates binding of lipopolysaccharide and Escherichia coli" EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 243, no. 1-2, 1997, pages 100-109, XP002458847 ISSN: 0014-2956 * abstract; tables 1-4 * -----	3,4	
Y	MAJERLE A ET AL: "Expression and Refolding of Functional Fragments of the Human Lipopolysaccharide Receptor CD14 in Escherichia coli and Pichia pastoris" PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 17, no. 1, October 1999 (1999-10), pages 96-104, XP004441631 ISSN: 1046-5928 * the whole document * ----- -/-	3,4	TECHNICAL FIELDS SEARCHED (IPC)
2	The supplementary search report has been based on the last set of claims valid and available at the start of the search.		
Place of search		Date of completion of the search	Examiner
Munich		19 November 2007	RENGGLI-ZULLIGER, N
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			



European Patent
Office

**SUPPLEMENTARY
EUROPEAN SEARCH REPORT**

Application Number

EP 05 73 9312

DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)								
Category	Citation of document with indication, where appropriate, of relevant passages										
A, P	<p>IWAKI D ET AL: "The CD14 region spanning amino acids 57-64 is critical for interaction with the extracellular Toll-like receptor 2 domain" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 328, no. 1, 4 March 2005 (2005-03-04), pages 173-176, XP004723755 ISSN: 0006-291X * abstract; figure 2 *</p> <p>-----</p>	1-18									
The supplementary search report has been based on the last set of claims valid and available at the start of the search.											
2											
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td><td style="width: 33%;">Date of completion of the search</td><td colspan="2" style="width: 34%;">Examiner</td></tr> <tr> <td>Munich</td><td>19 November 2007</td><td colspan="2" rowspan="2">RENGGLI-ZULLIGER, N</td></tr> </table>				Place of search	Date of completion of the search	Examiner		Munich	19 November 2007	RENGGLI-ZULLIGER, N	
Place of search	Date of completion of the search	Examiner									
Munich	19 November 2007	RENGGLI-ZULLIGER, N									
<table border="0" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top;"> CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document </td><td style="width: 50%; vertical-align: top;"> T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document </td></tr> </table>				CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document	T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document						
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document	T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document										

专利名称(译)	新的可溶性CD14抗原		
公开(公告)号	EP1746104A4	公开(公告)日	2008-01-09
申请号	EP2005739312	申请日	2005-05-11
申请(专利权)人(译)	持田PHARMACEUTICAL CO. , LTD.		
当前申请(专利权)人(译)	持田PHARMACEUTICAL CO. , LTD.		
[标]发明人	FUKUSAKO SHOJI C O MOCHIDA PHARM CO LTD SHIKARAWA KAMON C O MOCHIDA PHARM CO LTD HIROSE JIRO C O MOCHIDA PHARM CO LTD		
发明人	FUKUSAKO, SHOJI, C/O. MOCHIDA PHARM. CO., LTD. SHIKARAWA, KAMON, C/O. MOCHIDA PHARM. CO., LTD. HIROSE, JIRO, C/O. MOCHIDA PHARM. CO., LTD.		
IPC分类号	C07K14/705 C12P21/02 G01N33/53 G01N33/531		
CPC分类号	C07K14/70596 G01N2333/70596 G01N2800/26		
优先权	2004141600 2004-05-11 JP		
其他公开文献	EP1746104B1 EP1746104A1		
外部链接	Espacenet		

摘要(译)

提供了一种可溶性CD14抗原，它是一种新型体内蛋白质，可用作诊断败血症的标志物，具有以下特征：1) 至3)：1) 当通过SDS-PAGE测量时，分子量为13±2kDa。非还原条件; 2) 氨基酸序列，其中SEQ ID NO：1的氨基酸序列存在于其N末端; 3) 与通过使用SEQ ID NO：2中所述的包含16个氨基酸残基的肽制备的抗体特异性结合抗原的能力; 和重组可溶性CD14片段。

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (IPC)
Category	Citation or document with indication, where appropriate, of relevant passages	Relevant document	
X, P	YASUNORI YAEHASHI ET AL: "Evaluation of a newly identified soluble CD14 subtype as a marker for systemic sepsis." IN: JOURNAL OF INFECTION AND CHEMOTHERAPY ; OFFICIAL JOURNAL OF THE JAPANESE SOCIETY OF INFECTIOUS DISEASES AND THE JAPANESE ASSOCIATION FOR INFECTIOUS DISEASES. SPRINGER-VERLAG, TO, Vol. 1, no. 1, 1 October 2005 (2005-10-01), pages 234-238, X0024584906 ISSN: 1437-7782 * the whole document	1-18	INV. C07K14/705 C12P21/02 G01N33/53 G01N33/531
X	BUFLER P ET AL: "Soluble lipopolysaccharide receptor (CD14) is present on the surface of monocytes from human monocytes and CD14 transfectants." EUROPEAN JOURNAL OF IMMUNOLOGY FEB 1995, vol. 25, no. 2, 5 February 1995 (1995-02), pages 604-610, X002458844 ISSN: 0014-2990 * abstract; figure 6; table 1 *	1.2.5	TECHNICAL FIELDS SEARCHED (IPC) C07K C12P
X	GRUNWALD U ET AL: "An enzyme-linked immunosorbent assay for the quantification of solubilized CD14 in biological fluids." JOURNAL OF IMMUNOLOGICAL METHODS 5 NOV 1992, vol. 155, no. 2, 5 November 1992 (1992-11-05), pages 229-236, X002458845 ISSN: 0022-1759 * abstract; table VI *	12-14	
Y	----- ----- The supplementary search report has been based on the last set of claims valid and available at the start of the search.	3-4, 6-11, 15-18	
Z	Munich	19 November 2007	RENGGLI-ZULLIGER, N
CATEGORY OF CITED DOCUMENTS			
X	particularly relevant if taken alone	A: theory or principle underlying the invention	
X	partly relevant if combined with another	B: earlier patent document, but publication, or disclosure, of which is not sufficient for determining the nature of the invention	
X	partly relevant if combined with another	C: document cited in the application	
O	non-written document	D: document cited in the prior art	
I	intermediate document	E: member of the same patent family, corresponding document	